TranScrip Strengthens its Board
News Oct 09, 2015
TranScrip has announced that it has made two recent additions to its Board, Dr Frank Armstrong and Dr Linda Summerton.
Dr Frank Armstrong was appointed a Partner of TranScrip and a member of its Board in September 2015. He brings extensive experience of growing organizations across all aspects of the current collaborative pharma environment.
Frank has been non-executive chairman of AIM listed Summit plc (LSE: SUMM) since June 2013 and also for the last year of RedX Pharma a company which listed on the London Stock Exchange in 2015. He has also previously held Chief Executive roles with five biotechnology companies (public and private) one of which was Fulcrum Pharma, an AIM-listed Professional Services Company that was sold to Private Equity Investors in 2009.
In the past Frank led Medical Science and Innovation (MSI) at Merck Serono and previously was Head of Worldwide Product Development at Bayer and Senior Vice President of Medical Research and Communications Group at Zeneca.
He is also currently the Chairman of Xceleron and Faron Pharmaceuticals and is a Non-Executive Director of Actino Pharma, Juniper Pharmaceuticals Inc (formerly Columbia Laboratores Inc) and Mereo Biopharma. He is a Member of the Scientific Advisory Board of Healthcare Royalty Partners and is also a Fellow of the Royal College of Physicians.
Dr Linda Summerton, a Senior Partner of TranScrip who heads up the Oncology business area, a successful and growing group in TranScrip, was also appointed to the Board in September 2015. Linda has extensive experience working in large pharmaceutical companies, small biotechnology companies and private equity ventures. She was Partner at Celtic Pharma Holdings Advisors LLP, where she was responsible for identifying assets for investment and managing assets once acquired, as a Board member and/ or member of the management team for Cantab Biopharmaceuticals, Novacta Biosystems Ltd. and Dialog Devices Ltd.
Before joining Celtic Pharma, Linda worked for 16 years in large pharmaceutical companies, predominantly in AstraZeneca where she held senior roles, including Product Director for Iressa and Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team (TAMT). She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, leading the portfolio steering committees for Oncology, Cardiovascular and CNS.
Flic Gabbay says “TranScrip is proud of its track record of long term support for large and small pharma companies. These two appointments strengthen TranScrip’s Board as the organization continues to extend its reach.”
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018